Quantum BioPharma Makes Strategic Investment in GameStop Corp.
Quantum BioPharma (NASDAQ: QNTM) has announced a strategic investment in GameStop Corp. (NYSE: GME), purchasing 2,000 shares. This move is part of the company's broader strategy to combat market corruption and enhance shareholder value. The company has recently appointed anti-market manipulation advocates including Kevin Malone as Board Advisor and Terry Lynch as Director.
The company is pursuing legal action against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD for alleged stock manipulation. Additionally, Quantum completed a debt settlement of US$40,000 through the issuance of Class B shares. Malone Wealth Ventures, LLC, which owns approximately 21.8% of Quantum's Class B shares, received 30,000 shares and 60,000 RSUs as consulting compensation.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato un investimento strategico in GameStop Corp. (NYSE: GME), acquistando 2.000 azioni. Questa iniziativa fa parte della strategia più ampia dell'azienda per combattere la corruzione di mercato e aumentare il valore per gli azionisti. Recentemente, la società ha nominato sostenitori contro la manipolazione del mercato, tra cui Kevin Malone come Consigliere del Board e Terry Lynch come Direttore.
L'azienda sta intraprendendo azioni legali contro CIBC World Markets e RBC Dominion Securities, chiedendo risarcimenti superiori a 700 milioni di dollari USA per presunta manipolazione azionaria. Inoltre, Quantum ha completato un accordo sul debito di 40.000 dollari USA tramite l'emissione di azioni di Classe B. Malone Wealth Ventures, LLC, che possiede circa il 21,8% delle azioni di Classe B di Quantum, ha ricevuto 30.000 azioni e 60.000 RSU come compenso per consulenza.
Quantum BioPharma (NASDAQ: QNTM) ha anunciado una inversión estratégica en GameStop Corp. (NYSE: GME), adquiriendo 2,000 acciones. Esta acción forma parte de la estrategia más amplia de la compañía para combatir la corrupción en el mercado y aumentar el valor para los accionistas. Recientemente, la empresa nombró a defensores contra la manipulación del mercado, incluyendo a Kevin Malone como Asesor del Consejo y a Terry Lynch como Director.
La compañía está tomando acciones legales contra CIBC World Markets y RBC Dominion Securities, buscando daños que superan los 700 millones de dólares estadounidenses por presunta manipulación de acciones. Además, Quantum completó un acuerdo de deuda de 40,000 dólares estadounidenses mediante la emisión de acciones Clase B. Malone Wealth Ventures, LLC, que posee aproximadamente el 21.8% de las acciones Clase B de Quantum, recibió 30,000 acciones y 60,000 RSU como compensación por consultoría.
Quantum BioPharma (NASDAQ: QNTM)는 GameStop Corp. (NYSE: GME)에 전략적 투자를 발표하며 2,000주를 매입했습니다. 이 조치는 시장 부패를 근절하고 주주 가치를 향상시키기 위한 회사의 광범위한 전략의 일환입니다. 최근 회사는 시장 조작 방지 옹호자인 Kevin Malone을 이사회 고문으로, Terry Lynch를 이사로 임명했습니다.
회사는 CIBC World Markets와 RBC Dominion Securities를 상대로 법적 조치를 진행 중이며, 주식 조작 혐의로 7억 달러 이상의 손해 배상을 청구하고 있습니다. 또한 Quantum은 클래스 B 주식 발행을 통해 4만 달러의 부채 합의를 완료했습니다. Malone Wealth Ventures, LLC는 Quantum 클래스 B 주식의 약 21.8%를 보유하고 있으며, 자문 보수로 30,000주와 60,000 RSU를 받았습니다.
Quantum BioPharma (NASDAQ : QNTM) a annoncé un investissement stratégique dans GameStop Corp. (NYSE : GME), en achetant 2 000 actions. Cette démarche s'inscrit dans la stratégie plus large de l'entreprise visant à lutter contre la corruption du marché et à accroître la valeur pour les actionnaires. La société a récemment nommé des défenseurs contre la manipulation du marché, notamment Kevin Malone en tant que conseiller du conseil d'administration et Terry Lynch en tant que directeur.
L'entreprise engage des actions en justice contre CIBC World Markets et RBC Dominion Securities, réclamant des dommages et intérêts dépassant 700 millions de dollars US pour manipulation présumée des actions. De plus, Quantum a finalisé un règlement de dette de 40 000 dollars US par l'émission d'actions de classe B. Malone Wealth Ventures, LLC, qui détient environ 21,8 % des actions de classe B de Quantum, a reçu 30 000 actions et 60 000 RSU en compensation de conseil.
Quantum BioPharma (NASDAQ: QNTM) hat eine strategische Investition in GameStop Corp. (NYSE: GME) bekannt gegeben und 2.000 Aktien erworben. Dieser Schritt ist Teil der umfassenderen Strategie des Unternehmens, Marktmanipulationen zu bekämpfen und den Aktionärswert zu steigern. Kürzlich ernannte das Unternehmen Befürworter gegen Marktmanipulation, darunter Kevin Malone als Berater des Vorstands und Terry Lynch als Direktor.
Das Unternehmen verfolgt rechtliche Schritte gegen CIBC World Markets und RBC Dominion Securities und fordert Schadensersatz in Höhe von über 700 Millionen US-Dollar wegen angeblicher Aktienmanipulation. Zusätzlich hat Quantum eine Schuldenregulierung in Höhe von 40.000 US-Dollar durch Ausgabe von Aktien der Klasse B abgeschlossen. Malone Wealth Ventures, LLC, das etwa 21,8 % der Klasse B-Aktien von Quantum besitzt, erhielt 30.000 Aktien und 60.000 RSUs als Beratungsvergütung.
- None.
- Significant share dilution through consulting compensation and debt settlement
- Deviation from core business focus on neurodegenerative therapies with GameStop investment
- Large ownership concentration with Malone Wealth Ventures holding 21.8% of Class B shares
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE: GME) to hold on the Company's balance sheet as a strategic investment. This move aligns with Quantum BioPharma's ongoing commitment to combating market corruption and enhancing shareholder value through prudent financial strategies and advocacy against manipulative trading practices.
The Company has been at the forefront of fighting market corruption, as evidenced by its recent appointments of advocates like Board Advisor Kevin Malone (see PR April 22, 2025) and Director Terry Lynch (see PR March 27, 2025), both known for their crusades against naked short selling and stock manipulation. Mr. Malone is the Chief Executive Officer and sole owner of Malone Wealth Ventures, LLC, an investment advisory firm based in California, which provides comprehensive asset management and investment advice to its clients with various strategies. Malone Wealth Ventures, LLC served as a consultant to the Company from April 22, 2025, and received 30,000 shares and 60,000 RSU’s of the Company’s Class B Subordinate Voting Shares (“Class B Shares”) as compensation for its consulting services. Malone Wealth Ventures, LLC currently owns, on behalf of its clients, 829,730 Class B Shares, representing approximately
The Company has also pursued aggressive legal action, including an amended complaint filed against CIBC World Markets, RBC Dominion Securities, and others seeking damages exceeding
In parallel, the Company continues to build shareholder value through initiatives such as its advancement of its Multiple Sclerosis Patented New Chemical Entity asset (see PR July 8 2025), the intention to declare a special dividend of contingent value rights tied to potential litigation settlements (see PR June 13 2025), and strategic private placements to fund growth. The acquisition of GameStop shares represents a further step in deploying capital toward undervalued assets with strong fundamentals, reflecting the Company's disciplined approach to asset management amid its core focus on developing treatments like Lucid-MS for multiple sclerosis.
“The Quantum team and I see the extreme value in GameStop going forward and the deep value the company has with
The Company also announces that it has completed a debt settlement in the amount of US
Malone Wealth Ventures, LLC served as a consultant to the Company from April 22, 2025, and received 30,000 Class B shares and 60,000 RSU’s of the Company as compensation for its consulting services.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains certain "forward-looking statements" within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements include the Company’s belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStock’s stock price. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStock stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
What is the size of Quantum BioPharma's (QNTM) investment in GameStop?
How much does Malone Wealth Ventures own in Quantum BioPharma stock?
What is the amount of damages Quantum BioPharma is seeking in its legal action?
How did Quantum BioPharma settle its recent debt?
What compensation did Malone Wealth Ventures receive for consulting services?
